36727-17-0

Upstream product

• 186581-53-3 diazomethane 
• 5156-00-3 2-methoxyterephthalic acid 
• 67-56-1 methanol 
• 867-89-0 1-dimethylamino-1-methoxyethylene 
• 2166-24-7 pyridazine-3,6-dicarboxylic acid dimethyl ester 
• 586-35-6 2-bromo-1,4-benzenedicarboxylic acid 
• 6342-72-9 dimethyl hydroxyterephthalate 
• 6482-24-2 2-Bromoethyl methyl ether 
• 636-94-2 2-hydroxyterephthalic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 79236-96-7 2-methoxy-4-(hydroxymethyl)-3-methoxybenzoate 
• 79236-95-6 1,4-bis(hydroxy--methyl)-2-methoxybenzene 
• 492458-31-8 2-methoxyterephthalohydrazide 
• 79304-99-7 3-t-butyl-1-(7-methoxy<2,2,9,9-D4><2,2>paracyclophan-4-yl)-5--phenylverdazyl 
• 79237-19-7 3-t-butyl-1-(7-methoxy<2,2,9,9-D4><2.2>paracyclophan-4-yl)-5--phenylformazan 
• 79305-00-3 3-t-butyl-1-(7-methoxy<2,2-D2><2,2>paracyclophan-4-yl)-5-phenylverdazyl 
• 79237-20-0 3-t-butyl-1-(7-methoxy<2,2-D2><2.2>paracyclophan-4-yl)-5-phenylformazan 
• 79236-97-8 methyl 4-(acetoxymethyl)-3-methoxybenzoate 
• 79237-00-6 1,4-bis(chloro--methyl)-2-methoxybenzene 
• 79237-01-7 1-chloromethyl-4-chloro--methyl-2-methoxybenzene 
• 79236-98-9 1-hydroxymethyl-4-hydroxy--methyl-2-methoxybenzene 
• 5156-00-3 2-methoxyterephthalic acid 

Relevant academic research and scientific papers

DIMER COMPOUNDS, AND USE IN BINDING TOXIC REPEATS OF RNA

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are dimeric inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING SAME

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1 ), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

Defect Engineering into Metal-Organic Frameworks for the Rapid and Sequential Installation of Functionalities

Postsynthetic treatments are well-known and important functionalization tools of metal-organic frameworks (MOFs). Herein, we have developed a practical and rapid postsynthetic ligand exchange (PSE) strategy using a defect-controlled MOF. An increase in the number of defects amounts to MOFs with enhanced rates of ligand exchange in a shorter time frame. An almost quantitative exchange was achieved by using the most defective MOFs. This PSE strategy is a straightforward method to introduce a functionality into MOFs including bulky or catalytically relevant moieties. Furthermore, some mechanistic insights into PSE were revealed, allowing for a sequential ligand exchange and the development of multifunctional MOFs with controlled ligand ratios.

ROMP-POLYMERIZABLE ELECTRON TRANSPORT MATERIALS BASED ON A BIS-OXADIAZOLE MOIETY

This invention relates generally to a solution processable norbornene monomer, poly(norbornene) homopolymer, and poly(norbornene) copolymer compounds containing a functionalized bis -oxadiazole side chain, and to an electron injecting/transporting layer, a hole -blocking layer, or an emissive material, organic electronic devices and compositions which include these compounds.